# BigHat Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bighat-biosciences

- Industry: Healthcare IT
- Headquarters: San Mateo, US
- Website: www.bighatbio.com
- Total disclosed funding: $179M
- Latest round: Series C (Sep 24, 2026)
- Investors on record: 20

## About

BigHat Biosciences, Inc. is a biotechnology company based in the US that focuses on developing innovative antibody therapies through its advanced Milliner platform, integrating synthetic biology and machine learning to tackle difficult diseases.Founded in 2019 and headquartered in San Mateo, US, BigHat Biosciences specializes in revolutionizing antibody therapy design. The company has successfully raised a total of USD 80.00 mn in funding, most recently in Series B on 17 April 2025, led by Section 32 with participation from several noteworthy investors, including 8VC and Amgen Ventures. Mark DePristo and Peyton Greenside established the firm, with Mark DePristo currently serving as CEO.BigHat Biosciences specializes in the design and development of antibody therapies utilizing its proprietary Milliner platform, which integrates synthetic biology and advanced machine learning technologies. This full-stack platform enables the rapid synthesis, purification, and characterization of hundreds of recombinant antibodies, targeting a range of challenging diseases, including various cancers and infectious diseases. By leveraging high-speed wet lab capabilities alongside machine learning, BigHat aims to create next-generation therapies that provide enhanced safety and efficacy through rational molecular design. The company collaborates with strategic partners in the biotechnology and pharmaceutical sectors, serving clients primarily in North America and Europe, where the demand for innovative therapeutic solutions continues to grow.BigHat Biosciences generates revenue through strategic partnerships and collaborations with leading pharmaceutical companies to advance the development of its therapeutic programs. These partnerships involve the sharing of resources and expertise, often structured around milestone payments and licensing agreements for proprietary technology and products. Clients benefit from BigHat’s innovative antibody engineering solutions, which streamline the drug discovery process. The business operates primarily on a B2B model, focusing on delivering tailored solutions for pharmaceutical partners seeking to enhance their therapeutic pipelines. The company has raised over USD 80.00 mn from top investors, supporting its ongoing research and development initiatives. In September 2026, BigHat Biosciences raised USD 75 million in series C funding co-led by DFJ Growth and Premji Invest, with participation from Catalio Capital Management, LG Technology Ventures, Sigmas Group, 8VC, Alexandria Venture Investments, Amgen Ventures, Andreessen Horowitz, GRIDS Capital, Intermountain Ventures, Merck Global Health Innovation Fund, Quadrille Capital, Section 32, and Eli Lilly & Company.

## Funding rounds

- Series C, Sep 24, 2026, $75M — Alexandria Venture Investments, Amgen Ventures, Premji Invest, Merck Global Health Innovation Fund, Andreessen Horowitz, Discovery Ventures, Eli Lilly & Company, Quadrille Capital, DFJ Growth, 8VC, Section 32, LG Technology Ventures, Intermountain Ventures, Catalio Capital Management, Sigmas Group, GRIDS Capital
- Series B, Jun 30, 2022, $80M — Amgen Ventures, Andreessen Horowitz, Bristol-Myers Squibb Company, Innovation Endeavors, AME Cloud Ventures, Quadrille Capital, 8VC, Gaingels, Section 32
- Series A, Jan 28, 2021, $19M — Andreessen Horowitz, Innovation Endeavors, AME Cloud Ventures, 8VC
- Seed, Oct 22, 2019, $5.3M — 8VC

## Investors

- 8VC (https://capitalatlas.ai/funds/8vc) — Seed, Series A, Series B, Series C
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series A, Series B, Series C
- Innovation Endeavors (https://capitalatlas.ai/funds/innovation-endeavors) — Series A, Series B
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Series A, Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B, Series C
- Bristol-Myers Squibb Company — Series B
- Quadrille Capital (https://capitalatlas.ai/funds/quadrille-capital) — Series B, Series C
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series C
- Premji Invest — Series C
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series C
- Discovery Ventures — Series C
- Eli Lilly & Company — Series C
- DFJ Growth (https://capitalatlas.ai/funds/dfj-growth) — Series C
- LG Technology Ventures (https://capitalatlas.ai/funds/lg-technology-ventures) — Series C
- Intermountain Ventures (https://capitalatlas.ai/funds/intermountain-ventures) — Series C
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series C
- Sigmas Group — Series C
- GRIDS Capital — Series C